UPDATE
: Monday, December 16, 2019
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Syntekabio, CHA Hospital to co-develop immunotherapy
Syntekabio said that it will develop immunotherapy agents jointly with CHA ...
by Lee Han-soo
|
2019-12-06 16:32
라인
Medpacto vows to become global company specializing in biomarker-based drugs
Medpacto, a subsidiary of Theregen ETEX, plans to develop Vactosertib, an i...
by Lee Han-soo
|
2019-12-06 15:03
라인
Petitioner demands broader benefit for ovarian cancer drug Zejula
The government granted insurance benefit to Takeda's ovarian cancer tre...
by Song Soo-youn
|
2019-12-06 15:02
라인
China OKs Humedix's hyaluronic acid filler
Humedix said that China's National Medical Products Administration (NMP...
by Lee Han-soo
|
2019-12-06 15:02
라인
‘Lynparza raises value of precision medicine as anticancer treatment’
AstraZeneca’s Lynparza (ingredient: olaparib), the first PARP (poly ADP rib...
by Kim Yun-mi
|
2019-12-05 16:05
라인
Roche Diabetes Care stresses ‘integrated personalized diabetes management’
Roche Diabetes Care emphasized the importance of “integrated personalized d...
by Park Gi-taek
|
2019-12-05 13:01
라인
‘Obesity treatment will drastically change next few years’
An Irish expert on obesity and diabetes said Wednesday that prospects for t...
by Lee Han-soo
|
2019-12-04 18:20
라인
'Insulin is safe, natural replacement therapy for diabetic patients'
In Korea, 20.9 percent of diabetic patients, who have a hemoglobin A1c (HbA...
by Lee Han-soo
|
2019-12-04 17:07
라인
SK Biopharm set to ensure superiority in antiepileptic drug
SK Biopharmaceuticals said it would begin to develop a second new drug for ...
by Jeong Sae-im
|
2019-12-04 16:18
라인
Hanmi licenses in US firm’s oral immunotherapy candidate
Hanmi Pharmaceutical said that it has licensed in FLX475, the world’s first...
by Lee Han-soo
|
2019-12-04 16:16
라인
ISU Abxis starts trial of Gaucher disease treatment in Australia
ISU Abxis said that it has started phase 1 clinical trial of Abcertin, an e...
by Lee Han-soo
|
2019-12-04 16:16
라인
Samyang Biopharm’s US subsidiary to work on new immunotherapy
Samyang Biopharm USA said Tuesday it has signed a deal to adopt a new immun...
by Jeong Sae-im
|
2019-12-03 15:37
라인
Ildong signs co-promotion contract with GSK Consumer Healthcare
Ildong pharmaceutical said that it will co-promote GSK Consumer Healthcare’...
by Lee Han-soo
|
2019-12-03 15:18
라인
Global diabetes group opens 5-day show in Busan
The International Diabetes Federation (IDF) 2019 conference kicked off for ...
by Lee Han-soo
|
2019-12-03 11:04
라인
LG Chem licenses in US firm’s diagnostic platform tech
LG Chem said that it has licensed in a molecular diagnostic platform techno...
by Lee Han-soo
|
2019-12-02 13:42
라인
Syntekabio views industry’s crisis as opportunity
Syntekabio said that it aims to become the world's first publicly-trade...
by Jeong Sae-im
|
2019-11-29 17:54
라인
S. Biomedics to test embryonic stem cell-derived spinal cord injury treatment
S. Biomedics said that the Ministry of Food and Drug Safety has approved a ...
by Lee Han-soo
|
2019-11-29 15:42
라인
Daewoong challenges gastric acid blocker K-Cab with Fexuprazan
Daewoong Pharmaceutical said its new drug Fexuprazan will challenge the pot...
by Jeong Sae-im
|
2019-11-29 15:23
라인
Hanmi's Chinese partner to start trials for anticancer treatment
Hanmi Pharmaceutical said its Chinese partner Innovent Biologics has begun ...
by Lee Han-soo
|
2019-11-28 17:38
라인
GI Innovation licenses out immunotherapy drug candidate to Chinese firm
GI Innovation said that it has licensed out GI-101, a bispecific fusion pro...
by Lee Han-soo
|
2019-11-28 16:26
-
1
2
3
4
5
6
7
8
9
10
다음
-
[News Focus] 'You, too, can use millions of patients’ data for research'
Celltrion secures 11 synthetic drugs to advance to US market
Dong-A, Meiji Seika to conduct P1 trial for Stelara biosimilar
Patient cries for stem cell therapy approval to stop heart necrosis
[News Focus] 'You, too, can use millions of patients’ data for research'
Celltrion secures 11 synthetic drugs to advance to US market
Dong-A, Meiji Seika to conduct P1 trial for Stelara biosimilar
Patient cries for stem cell therapy approval to stop heart necrosis
여백
Most viewed
1
ABL Bio unveils new bispecific antibody at US meet
2
Aprogen, 1st Korean biotech firm to win unicorn status
3
Sanofi, Hanmi to look for new partner to commercialize efpeglenatide
4
Curexo launches 1st locally developed spine surgery robot
5
Samsung execs get jail term for destroying evidence
6
Samsung Bioepis to start P3 trial for Ontruzant in China
7
Eli Lilly Korea launches migraine prevention drug
8
Korean physician 1st Asian to do 1,000 robotic myomectomy surgeries
9
[Reporter's Notebook] Korean biopharmaceuticals have long way to go before reaching foreigners
10
SK Bioscience's chickenpox vaccine world's 2nd to get WHO’s PQ certification
여백
Opinion
[Reporter's Notebook] Korean biopharmaceuticals have long way to go before reaching foreigners
[Column] Korea should do better in diabetes management
[Column] Digital healthcare for efficient distribution of medical resources
여백
Back to Top